By Stacy M. Brown | NNPA (NNPA) - The U.S. Food and Drug Administration (FDA) has greenlit two revolutionary cell-based gene therapies, Casgevy and Lyfgenia, marking a significant leap forward in treating sickle cell disease (SCD) for patients aged 12 and older. The approval by the FDA signifies the commencement of a novel epoch in […]
The post FDA Approves Groundbreaking Cell-Based Gene Therapies for Sickle Cell Disease appeared first on The Sacramento Observer.